Pulse Biosciences
PLSE
45.55
+1.14
+2.57%
Pulse Biosciences
US · PLSE
#2388 by market cap
Listed 2016
45.55
+1.14
+2.57%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Pulse Biosciences
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.
- Founded
- 2014
- CEO
- Mr. Paul A. Laviolette
- Employees
- 116
- Headquarters
- Miami, Florida, United States of America
- Fiscal year end
- 12-31
- Website
- pulsebiosciences.com
Company profile
- Exchange
- US
- Symbol
- PLSE
- Market-cap rank
- #2388
- Listing date
- 2016-05-18
- Market cap
- 3.35B
- Float cap
- 1.04B
- Shares out
- 73.55M
- Float shares
- 22.88M
Sectors & themes
Medical Instruments & Supplies
Fractional Shares JP
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Pulse Biosciences discussion 0 comments